EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

Susumu Kobayashi, Titus J. Boggon, Tajhal Dayaram, Pasi A. Jänne, Olivier Kocher, Matthew Meyerson, Bruce E. Johnson, Michael J. Eck, Daniel G. Tenen, Balazs Halmos

Research output: Contribution to journalArticle

2902 Citations (Scopus)

Abstract

Mutations of the epidermal growth factor receptor (EGFR) gene have been identified in specimens from patients with non-small-cell lung cancer who have a response to anilinoquinazoline EGFR inhibitors. Despite the dramatic responses to such inhibitors, most patients ultimately have a relapse. The mechanism of the drug resistance is unknown. Here we report the case of a patient with EGFR-mutant, gefitinib-responsive, advanced non-small-cell lung cancer who had a relapse after two years of complete remission during treatment with gefitinib. The DNA sequence of the EGFR gene in his tumor biopsy specimen at relapse revealed the presence of a second point mutation, resulting in threonine-to-methionine amino acid change at position 790 of EGFR. Structural modeling and biochemical studies showed that this second mutation led to gefitinib resistance.

Original languageEnglish (US)
Pages (from-to)786-792
Number of pages7
JournalNew England Journal of Medicine
Volume352
Issue number8
DOIs
StatePublished - Feb 24 2005
Externally publishedYes

Fingerprint

Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
erbB-1 Genes
Recurrence
Mutation
Threonine
Point Mutation
Drug Resistance
Methionine
Biopsy
Amino Acids
gefitinib
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., ... Halmos, B. (2005). EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. New England Journal of Medicine, 352(8), 786-792. https://doi.org/10.1056/NEJMoa044238

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. / Kobayashi, Susumu; Boggon, Titus J.; Dayaram, Tajhal; Jänne, Pasi A.; Kocher, Olivier; Meyerson, Matthew; Johnson, Bruce E.; Eck, Michael J.; Tenen, Daniel G.; Halmos, Balazs.

In: New England Journal of Medicine, Vol. 352, No. 8, 24.02.2005, p. 786-792.

Research output: Contribution to journalArticle

Kobayashi, S, Boggon, TJ, Dayaram, T, Jänne, PA, Kocher, O, Meyerson, M, Johnson, BE, Eck, MJ, Tenen, DG & Halmos, B 2005, 'EGFR mutation and resistance of non-small-cell lung cancer to gefitinib', New England Journal of Medicine, vol. 352, no. 8, pp. 786-792. https://doi.org/10.1056/NEJMoa044238
Kobayashi S, Boggon TJ, Dayaram T, Jänne PA, Kocher O, Meyerson M et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. New England Journal of Medicine. 2005 Feb 24;352(8):786-792. https://doi.org/10.1056/NEJMoa044238
Kobayashi, Susumu ; Boggon, Titus J. ; Dayaram, Tajhal ; Jänne, Pasi A. ; Kocher, Olivier ; Meyerson, Matthew ; Johnson, Bruce E. ; Eck, Michael J. ; Tenen, Daniel G. ; Halmos, Balazs. / EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. In: New England Journal of Medicine. 2005 ; Vol. 352, No. 8. pp. 786-792.
@article{a211bdd014214a01a023ab54cf19ed1f,
title = "EGFR mutation and resistance of non-small-cell lung cancer to gefitinib",
abstract = "Mutations of the epidermal growth factor receptor (EGFR) gene have been identified in specimens from patients with non-small-cell lung cancer who have a response to anilinoquinazoline EGFR inhibitors. Despite the dramatic responses to such inhibitors, most patients ultimately have a relapse. The mechanism of the drug resistance is unknown. Here we report the case of a patient with EGFR-mutant, gefitinib-responsive, advanced non-small-cell lung cancer who had a relapse after two years of complete remission during treatment with gefitinib. The DNA sequence of the EGFR gene in his tumor biopsy specimen at relapse revealed the presence of a second point mutation, resulting in threonine-to-methionine amino acid change at position 790 of EGFR. Structural modeling and biochemical studies showed that this second mutation led to gefitinib resistance.",
author = "Susumu Kobayashi and Boggon, {Titus J.} and Tajhal Dayaram and J{\"a}nne, {Pasi A.} and Olivier Kocher and Matthew Meyerson and Johnson, {Bruce E.} and Eck, {Michael J.} and Tenen, {Daniel G.} and Balazs Halmos",
year = "2005",
month = "2",
day = "24",
doi = "10.1056/NEJMoa044238",
language = "English (US)",
volume = "352",
pages = "786--792",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "8",

}

TY - JOUR

T1 - EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

AU - Kobayashi, Susumu

AU - Boggon, Titus J.

AU - Dayaram, Tajhal

AU - Jänne, Pasi A.

AU - Kocher, Olivier

AU - Meyerson, Matthew

AU - Johnson, Bruce E.

AU - Eck, Michael J.

AU - Tenen, Daniel G.

AU - Halmos, Balazs

PY - 2005/2/24

Y1 - 2005/2/24

N2 - Mutations of the epidermal growth factor receptor (EGFR) gene have been identified in specimens from patients with non-small-cell lung cancer who have a response to anilinoquinazoline EGFR inhibitors. Despite the dramatic responses to such inhibitors, most patients ultimately have a relapse. The mechanism of the drug resistance is unknown. Here we report the case of a patient with EGFR-mutant, gefitinib-responsive, advanced non-small-cell lung cancer who had a relapse after two years of complete remission during treatment with gefitinib. The DNA sequence of the EGFR gene in his tumor biopsy specimen at relapse revealed the presence of a second point mutation, resulting in threonine-to-methionine amino acid change at position 790 of EGFR. Structural modeling and biochemical studies showed that this second mutation led to gefitinib resistance.

AB - Mutations of the epidermal growth factor receptor (EGFR) gene have been identified in specimens from patients with non-small-cell lung cancer who have a response to anilinoquinazoline EGFR inhibitors. Despite the dramatic responses to such inhibitors, most patients ultimately have a relapse. The mechanism of the drug resistance is unknown. Here we report the case of a patient with EGFR-mutant, gefitinib-responsive, advanced non-small-cell lung cancer who had a relapse after two years of complete remission during treatment with gefitinib. The DNA sequence of the EGFR gene in his tumor biopsy specimen at relapse revealed the presence of a second point mutation, resulting in threonine-to-methionine amino acid change at position 790 of EGFR. Structural modeling and biochemical studies showed that this second mutation led to gefitinib resistance.

UR - http://www.scopus.com/inward/record.url?scp=13844317894&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13844317894&partnerID=8YFLogxK

U2 - 10.1056/NEJMoa044238

DO - 10.1056/NEJMoa044238

M3 - Article

C2 - 15728811

AN - SCOPUS:13844317894

VL - 352

SP - 786

EP - 792

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 8

ER -